Sanofi said the results are strong enough to support a new indication in the US and EU for Libtayo, a PD-1 inhibitor that is already FDA-approved in advanced cutaneous squamous cell carcinoma.

It's been cleared for second-line use in patients who have progressed or are intolerant to hedgehog inhibitor therapy. Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out ...

R egeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy ...